🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-518780-36-00
Completed Phase I

A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)

2024-518780-36-00 · tracked via the Priya Life Science EU tracker
Sponsor
Cullinan Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Musculoskeletal Diseases
Decision date
25/11/2025
Enrollment target
44
Sites
Bulgaria, Romania, France, Germany, Spain, Poland

Condition studied

Systemic Lupus Erythematosus

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-518780-36-00 on CTIS ↗ ← All trials in the EU